GlassScriptPhysician profile
David R Rose
NPI 1215154158
$18,359.79
in general payments reported to CMS, 2019-2025
18 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,641 · 2020: $1,401 · 2021: $2,526 · 2022: $667 · 2023: $3,274 · 2024: $673 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $1,214 · Travel and Lodging: $1,111 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $1,213.59 |
| Travel and Lodging | $1,110.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12,886.29 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $3,843.39 | 2022-2025 | Infuse, Miebo |
| Kala Pharmaceuticals, INC. | $353.76 | 2021-2022 | |
| Notal Vision, INC. | $213.38 | 2022 | |
| Sun Pharmaceutical Industries INC. | $180.30 | 2020-2021 | |
| Biotissue Holdings INC. | $155.77 | 2024 | |
| Alcon Vision LLC | $134.59 | 2025 | Dailies Total1 |
| Tarsus Pharmaceuticals, INC. | $108.64 | 2024 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $105.71 | 2019-2023 | Acuvue |
| Allergan, INC. | $75.51 | 2021 | |
| Abbvie INC. | $62.96 | 2022-2023 | Lumigan |
| Carl Zeiss Meditec USA, INC. | $59.20 | 2023 | Clarus |
| Oasis Medical, INC. | $57.50 | 2023 | Oasis Tears |
| Oyster Point Pharma, INC. | $33.87 | 2023-2024 | Tyrvaya |
| Shire North American Group INC | $32.43 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $24.70 | 2024 | Iyuzeh |
| Coopervision INC. | $16.66 | 2023 | Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $15.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.